
(IN BRIEF) Researchers at Newcastle University have discovered a new biological mechanism explaining why some patients do not respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. They identified T regulatory cells (Tregs) as key drivers of ICB … Read the full press release